Healthcare & Life Sciences
Midland Pharmaceuticals
United Kingdommidlandpharmaceuticals.com
activeseries-a
series-a
Stage
1
Investors
About
Midland Pharmaceuticals is a clinical stage pharmaceutical company focused on developing therapeutics for spinal cord injury and stroke. The company is developing MLP-1236, a first-in-class dual inhibitor of MMP-9 and MMP-12 enzymes implicated in the inflammatory process following central nervous system injury.
Explore Midland Pharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.